Table 5.
Adverse events experienced by the patients
| CTCAE grade I | CTCAE grade II | CTCAE grade III | ||
|---|---|---|---|---|
| Fatigue (number of patients) | 26 [40.0%] | – | – | |
| Fatigue (number of events) | Acute | 3 [4.6%] | – | – |
| After 3 months | 10 [15.4%] | – | – | |
| After 6 months | 9 [13.8%] | – | – | |
| After 9 months | 7 [10.8%] | – | – | |
| After 12 months | 6 [9.2%] | – | – | |
| After 15 months | 5 [7.7%] | – | – | |
| After 18 months | 3 [4.6%] | – | – | |
| Cephalgia (number of patients) | 8 [12.3%] | 1 [1.5%] | – | |
| Cephalgia (number of events) | Acute | 2 [3.1%] | – | – |
| After 3 months | 3 [4.6%] | – | – | |
| After 6 months | 4 [6.2%] | 1 [1.5%] | – | |
| After 9 months | 4 [6.2%] | – | – | |
| After 12 months | 1 [1.5%] | – | – | |
| After 15 months | 1 [1.5%] | – | – | |
| Vertigo (number of patients) | 10 [15.4%] | – | – | |
| Vertigo (number of events) | Acute | 6 [9.2%] | – | – |
| After 6 months | 4 [6.2%] | – | – | |
| After 9 months | 2 [3.1%] | – | – | |
| After 12 months | 1 [1.5%] | – | – | |
| After 15 months | 2 [3.1%] | – | – | |
| After 18 months | 1 [1.5%] | – | – | |
| Motoric impairment (number of patients) | 1 [1.5%] | – | – | |
| Motoric impairment (number of events) | After 3 months | 1 [1.5%] | – | – |
| After 9 months | 1 [1.5%] | – | – | |
| Sensitivity disorder (number of patients) | 2 [3.1%] | – | – | |
| Sensitivity disorder (number of events) | After 6 months | 2 [3.1%] | – | – |
| After 9 months | 1 [1.5%] | – | – | |
| Aphasia (number of patients) | 1 [1.5%] | – | – | |
| Aphasia (number of events) | Acute event | 1 [1.5%] | – | – |
| After 6 months | 1 [1.5%] | – | – | |
| Neurocognitive impairment (number of patients) | 18 [27.7%] | – | – | |
| Neurocognitive impairment (number of events) | Acute | 2 [3.1%] | – | – |
| After 3 months | 4 [6.2%] | – | – | |
| After 6 months | 1 [1.5%] | – | – | |
| After 9 months | 8 [12.3%] | – | – | |
| After 12 months | 3 [4.6%] | – | – | |
| After 15 months | 3 [4.6%] | – | – | |
| Atfer 18 months | 2 [3.1%] | – | – | |
| Seizure (number of patients) | 4 [6.2%] | – | 3 [4.6%] | |
| Seizure (number of events) | Acute event | – | 1 [1.5%] | – |
| After 3 months | 1 [1.5%] | 1 [1.5%] | 2 [3.1%] | |
| After 6 months | 1 [1.5%] | – | – | |
| After 9 months | – | – | 1 [1.5%] | |
| Alopecia (number of patients) | 7 [10.8%] | 2 [3.1%] | – | |
| Alopecia (number of events) | After 3 months | 4 [6.2%] | 2 [3.1%] | – |
| After 6 months | 2 [3.1%] | – | – | |
| After 9 months | 1 [1.5%] | – | – | |
| After 12 months | 1 [1.5%] | – | – | |
| After 15 months | 1 [1.5%] | – | – | |
| Radiation necrosis (number of symptomatic patients) | – | – | – | |
| Paresis left arm | After 1 month | 1 [1.5%] | – | – |
| Vertigo | After 3 months | 1 [1.5%] | – | – |
| Vertigo, nystagmus | After 6 months | 1 [1.5%] | – | – |